Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 24,647	$ 16,512
Marketable securities	70,323	18,061
Prepaid and other current assets	1,212	758
Total current assets	96,182	35,331
Property and equipment, net	62	57
Other assets	764	614
Total assets	97,008	36,002
Liabilities
Accounts payable	1,934	1,020
Accrued liabilities	2,589	2,486
Total current liabilities	4,523	3,506
Other long-term liabilities	485	254
Total liabilities	5,008	3,760
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively	60	19
Additional paid-in capital	545,988	458,748
Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively	(708)	(708)
Accumulated deficit	(453,016)	(425,550)
Accumulated other comprehensive loss	(70)	(13)
Total Caladrius Biosciences, Inc. stockholders' equity	92,254	32,496
Non-controlling interests	(254)	(254)
Total equity	92,000	32,242
Total liabilities, non-controlling interests and equity	$ 97,008	$ 36,002